The global atrial fibrillation (AFib) device market is on a strong growth trajectory, with total sales projected to rise from USD 4,628.90 million in 2024 to a remarkable USD 13,025.40 million by 2034, according to the latest industry analysis. This growth is driven by a 10.9% CAGR over the forecast period, as the demand for advanced cardiac care solutions continues to rise.
Atrial fibrillation, a condition marked by an irregular and often rapid heart rhythm, poses a significant health risk due to its association with stroke and blood clots. AFib devices, which include ablation catheters, diagnostic catheters, laboratory devices, and access devices, are critical in managing this condition. Among these, ablation catheters are expected to dominate the market, holding a 58.60% share due to their effectiveness in restoring normal heart rhythm through minimally invasive procedures.
Hospitals remain the primary end-user for atrial fibrillation devices, accounting for 61.8% of total revenue. This dominance is attributed to the high volume of cardiac procedures performed in hospital settings, along with the growing availability of advanced treatment technologies. As the prevalence of AFib continues to rise globally, healthcare providers are prioritizing investments in modern cardiac care devices, further boosting market growth.
The global atrial fibrillation device market presents a promising growth opportunity for device manufacturers, healthcare providers, and investors. With a growing aging population and rising awareness of cardiac health, the demand for innovative, patient-centric solutions is expected to accelerate. Companies with a focus on minimally invasive, precise, and efficient devices are well-positioned to lead the market over the next decade.
Key Takeaways:
- Market Valuation: Global atrial fibrillation device sales are projected to reach USD 4,628.90 million by 2024 and climb to USD 13,025.40 million by 2034.
- Growth Momentum: The market will grow at a CAGR of 10.9% from 2024 to 2034.
- 2023 Revenue Benchmark: Market revenue stood at USD 4,173.90 million in 2023, reflecting significant year-on-year growth.
- Market Leaders: Ablation catheters are expected to lead the market with a 58.60% share, while hospitals remain the key end-user segment, accounting for 61.8% of total revenue.
Market Drivers
- Increasing Prevalence of Atrial Fibrillation: AFib is the most common cardiac arrhythmia, affecting a significant portion of the population and driving demand for effective management solutions.
- Technological Advancements: Innovations in AFib devices, particularly in ablation catheters, are enhancing treatment efficacy and patient outcomes. Ablation catheters are expected to dominate the market, accounting for approximately 58.6% of the market share.
- Focus on Minimally Invasive Procedures: The trend towards minimally invasive surgical techniques is increasing the adoption of AFib devices, as they offer reduced recovery times and lower complication rates compared to traditional surgical methods.
- Growing Awareness and Diagnosis: Increased awareness of AFib and advancements in diagnostic technologies are leading to earlier detection and treatment, further boosting market growth.
- Support from Healthcare Institutions: Hospitals represent a significant segment of the market, contributing approximately 61.8% to revenue growth due to their role as primary providers of AFib treatment.
Competitive Landscape
Key players operating in the atrial fibrillation device market are focusing on research and development to build innovative solution and get regulatory approval for it. Large established market player are incorporating strategies such as collaboration to increase their market reach. The main cornerstone for the market player is make product that emphasis evidence based clinical practice.
Recent Industry Developments in Atrial Fibrillation Device Market
- In January 2024, Boston Scientific Corporation disclosed that it has received FDA approval for FARAPULSE, which is a pulsed field ablation (PFA) system. FARAPULSE is used for isolation of pulmonary veins in the treatment of atrial fibrillation.
- In December 2023, Medtronic plc announced the FDA approval of PulseSelect Pulsed Field Ablation (PFA) System. It is used for treatment of persistent and paroxysmal atrial fibrillation (atrial fibrillation).
- In August 2023, GE Healthcare announced the launch of CardioVision. It is used for atrial fibrillation (atrial fibrillation). It is digital tool that assist clinicians in visualizing longitudinal data from multiple data sources that is relevant to the disease progression.
Key Players of Atrial Fibrillation Device Industry
- Biosense Webster, Inc
- Abbott Laboratories
- Medtronic Plc
- Boston Scientific Corporation
- GE Healthcare
- Siemens Healthineers AG
- Koninklijke Philips N.V.
- Japan Lifeline Co. Ltd.
- Stereotaxis, Inc.
- Microport Scientific Corporation
- AtriCure, Inc.
- Biotronik SE & Co. KG
- Acutus Medical Inc.
- Baylis Medical Company, Inc.
- EP Solutions
- Teleflex
- Merit Medical Systems Inc.
- Biomerics
Key Segments of Atrial Fibrillation Device Industry
By Product:
In terms of product, the industry is divided into laboratory devices (3D mapping systems, EP recording systems, RF ablation systems, ICE systems, cardiac stimulators, and others), ablation catheters (cryoablation, RF ablation, irrigated tip RF, laser), diagnostic catheters (conventional, advanced, and ultrasound), and access devices.
By End User:
By end user, the industry is bifurcated into hospitals, ambulatory surgical centers, and cardiac catheterization laboratories.
By Region:
Key countries of North America, Latin America, East Asia, South Asia, Western Europe, Eastern Europe, and Middle East and Africa (MEA), have been covered in the report.
Explore FMI’s Related Ongoing Coverage on Healthcare Market Insights Domain:
Protein A Resins Market – https://www.futuremarketinsights.com/reports/protein-a-resins-market
Platelet Rich Plasma Market – https://www.futuremarketinsights.com/reports/platelet-rich-plasma-market
Saudi Arabia Pharmaceutical Market – https://www.futuremarketinsights.com/reports/saudi-arabia-pharmaceutical-market
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube